Bleakley Financial Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Bleakley Financial Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,302	Closed	-$3.78M	–	882
2024 Q4	$3.78M	Sell	5,302 -613	-10%	-$514K	0.11%	152
2024 Q3	$6.22M	Sell	5,915 -7,714	-57%	-$8.58M	0.19%	94
2024 Q2	$14.3M	Sell	13,629 -751	-5%	-$728K	0.41%	41
2024 Q1	$13.8M	Buy	14,380 +5,403	+60%	+$5.14M	0.4%	43
2023 Q4	$7.88M	Buy	8,977 +860	+11%	+$708K	0.25%	76
2023 Q3	$6.68M	Sell	8,117 -3,400	-30%	-$2.67M	0.24%	83
2023 Q2	$8.28M	Buy	11,517 +188	+2%	+$145K	0.26%	77
2023 Q1	$9.31M	Buy	11,329 +437	+4%	+$330K	0.31%	66
2022 Q4	$7.86M	Buy	+10,892	New	+$8.04M	0.28%	69

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bleakley Financial Group's REGN Position: Q1 2025 in Review

Bleakley Financial Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 5,302 shares — an estimated $3.78M sold.

Bleakley Financial Group first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $14.3M in Q2 2024. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

Bleakley Financial Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bleakley Financial Group sold 5,302 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $3.78M.
Bleakley Financial Group first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Bleakley Financial Group's Regeneron Pharmaceuticals position peaked at $14.3M in Q2 2024.
1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.